RecruitMe Clinical Trial

Cannabinoid Medication for Adults With OCD
Cannabinoids and OCD
Sponsor:New York State Psychiatric Institute
Enrolling:Male and Female Patients
Age Range:Between 18 and 60 years old
IRB Number:7239
U.S. Government ID:NCT02911324
Contact: Ivar Snorrason: 646-774-8118 / snorras@nyspi.columbia.edu
Additional Study Information:

The purpose of this pilot research study is to test the effects of a medication called nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will receive either nabilone on its own, or nabilone in combination with a form of cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.

Do You Qualify?
Are you between the ages of 18 and 60?YesNo
Do you have bothersome OCD symptoms?YesNo
Are you currently taking any psychiatric medications?YesNo
Investigator
Helen Simpson, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:

Ivar Snorrason

snorras@nyspi.columbia.edu

646-774-8118

YesYesNo3